The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Immune checkpoint inhibitors in challenging populations
Open accessAbstract
Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice have not qualified for or have been seriously underrepresented in immune checkpoint inhibitor clinical trials. Thus, a major gap in knowledge regarding the safety and efficacy of these agents persists in many populations, even after regulatory approval. To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical populations to assist both academic and community oncologists in treatment decision making. Specifically, this review focuses on the safety and activity of immune checkpoint inhibitors in patients with autoimmune disorders, organ transplant patients, patients with chronic viral infections, patients with ongoing immunosuppressant use, patients with organ dysfunction, pregnant patients, patients with brain metastases, patients at extremes of age, and patients with an impaired functional status. Cancer 2017;123:1904-1911. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the safety and effectiveness of ICI therapy in this special population are unknown.34”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
Self-citationRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Flagged first, then by citations
Research works printed but not linked: 1
- Bethof A, 2015, Age on outcome and toxicity with anti–PD‐1/PD‐L1 therapy in patients with melanoma [abstract], Pigment Cell Melanoma Res, 28, 756
Cited by
Sorted by citations
Items 301–339 of 339
Chang, H. J., & Bercovitch, L. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-56861-0_16
Nebenwirkungsmanagement unter Checkpoint-Inhibitor-Therapie
Schmale, I. (2021) · Onkologische Welt · doi:10.1055/a-1400-8688
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Davies, M. J., & Russo, A. V. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_7
Heng, W. S. (2022) · doi:10.33612/diss.196891514
Zhang, Y., Wang, Y., Wang, J., & Zhang, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1219557/v1
Decoster, L., & Aspeslagh, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_766
Gestational trophoblastic disease
Nica, A., Bouchard‐Fortier, G., & Covens, A. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-65399-2.00043-7
Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysisPreprint
Yamaguchi, A., Saito, Y., Okamoto, K., Narumi, K., Furugen, A., Takekuma, Y., Sugawara, M., & Kobayashi, M. (2021) · Research Square · doi:10.21203/rs.3.rs-403836/v1
Decoster, L., & Aspeslagh, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-69892-2_766-1
McAlister, R. K. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.melanoma_overview
Current Status of Immune Checkpoint Inhibitors in the Broncho-Esophagological Field
Murayama, M., Hosonuma, M., Kuramasu, A., & Yoshimura, K. (2022) · Nihon Kikan Shokudoka Gakkai Kaiho · doi:10.2468/jbes.73.308
Omar, N. E., Afifi, H. M., Sahal, A., Mekkawi, R., & Elewa, H. F. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107833
Drug Targets and Strategies in the Clinical Development of Immunotherapy for Head and Neck Cancer
van der Elst, A., & Machiels, J. (2022) · Cancer immunotherapy · doi:10.1007/13905_2022_27
Medikamentöse Tumortherapie des älteren Menschen
Deschler-Baier, B., & Hartmann, S. (2022) · Springer eBooks · doi:10.1007/978-3-662-62808-9_11
Immune Responses to Solid Tumors and Immune Checkpoint Therapy
Das, S., Balko, J. M., & Johnson, D. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00080-0
Do corticosteroids affect immunotherapy efficacy in malignancy? – A systematic reviewPreprint
Byron, Y., Yegorova‐Lee, S., & Tio, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3578070/v1
Masiuk, D. M., Nedzvetsky, V. S., & Кокарєв, А. В. (2023) · doi:10.30525/978-9934-26-395-8-12
81-Year-Old Woman With Hemoptysis
Liddell, S. S., Hwang, S. R., & Szostek, J. H. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.10.025
Ortiz‐Urda, S., Ho, W., & Lee, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59128-0_9
Engineered Nanomaterials Chemical Characteristics for Cancer Immunotherapy
Islam, M. A., Chowdhury, M. S., Hasan, M. J., Rayhan, M. T., Islam, S., Hossain, N., & Mobarak, M. H. (2024) · Nano LIFE · doi:10.1142/s1793984424300127
Liu, M., Li, Q., Meng, X., Cui, Y., Sun, W.-R., Wang, H., & Gao, Q. (2024) · Medicine · doi:10.1097/md.0000000000040569
Cancerul de sân în timpul sarcinii: review
Băţ, D., Cloţea, E., Gică, N., Petca, A. T., Atanasescu, I.-E., Francesca, S., Mehedințu, C., & Nodiți-Cuc, A.-R. (2024) · Obstetrica şi Ginecologia · doi:10.26416/obsgin.72.3.2024.10389
Yang, H., Yu, S., & Ge, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1539260
Huynh, J., Eigentler, T., Moritz, R. K. C., Poch, G., Schlaak, M. S., & Dobos, G. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15695
Evaluation of PD-L1 expression and its prognostic implications in canine mammary tumors
Devaraj, C. K., Anjan Kumar, K. R., Koppad, S., Shankar, B. P., Pavithra, B. H., Murthy, K. S., & Jayaramu, G. M. (2025) · International Journal of Advanced Biochemistry Research · doi:10.33545/26174693.2025.v9.i6sd.4539
Grossesse après cancer du sein
Loison, R., & de Castelbajac, V. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.04.001
Rao, H., Xie, W.-C., Guo, F., & Chen, H.-W. (2025) · Discover Oncology · doi:10.1007/s12672-025-03145-3
Huynh, J., Eigentler, T., Moritz, R. K. C., Poch, G., Schlaak, M. S., & Dobos, G. (2025) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15695_g
Immunotherapy for Breast Cancer
Costa, K. M. N., de Melo, D. F., Soares, I. L. D. S., Damasceno, B. P. G. D. L., & Oshiro, J. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_224
Saber, R., Henault, D., Messaoudi, N., Rebolledo, R., Montagnon, E., Soucy, G., Stagg, J., Tang, A., Turcotte, S., & Kadoury, S. (2024) · Figshare · doi:10.6084/m9.figshare.26607052
Guadagni, S., Fiorentini, G., Papasotiriou, I., Apostolou, P., Masedu, F., Sarti, D., Farina, A. R., Mackay, A. R., & Clementi, M. (2020) · Figshare · doi:10.6084/m9.figshare.12023895
Holmes, A. N., Swede, H., Feer, W. M., Pike, D. C., Wang, X., & Hegde, U. P. (2021) · Figshare · doi:10.6084/m9.figshare.17133019
Ribeiro, S. C. C. R., Balbi, G. G. M., Bunjes, B. G., Silva, M. J. B., & de Andrade, D. C. O. (2026) · Brazilian Journal of Oncology · doi:10.1055/s-0045-1814174
Peterson, A. M., Stwalley, D. L., Kallogjeri, D., Barrett, T. F., Harbison, A., Pipkorn, P. J., Jackson, R. S., Puram, S. V., Piccirillo, J. F., & Zolkind, P. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2025.5513
Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Associated Sicca Syndrome
Balbach, M. L., & Johnson, D. B. (2026) · Cancers · doi:10.3390/cancers18111836
Li, J., Dong, S., Hu, D., & Feng, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1853596
Clinical Syndromes of Peripheral Nervous System Neurotoxicity from Immune-Checkpoint Inhibitors
Smith, I., Choi, M., & Sabadia, S. B. (2026) · Seminars in Neurology · doi:10.1055/a-2936-5945
Kalluri, U., & Subair, M. N. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1665
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., & Menzies, A. M.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- The University of Sydney (AU)
- Corresponding author
- Johnson, Douglas B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-02-27
- Volume
- 123
- Issue
- 11
- Pages
- 1904-1911
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC5445005
- OpenAlex
- W2592187743
- Cited by
- 339
- References
- 78
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 21 · 2023: 32 · 2022: 42 · 2021: 58 · 2020: 71 · 2019: 42 · 2018: 23 · 2017: 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K23 CA204726)
- Cancer Institute NSW
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, PD-1/PD-L1 pathway, underrepresented groups, autoimmune disease, organ transplant recipients, chronic viral infection, immunosuppressants, organ dysfunction, pregnancy, brain metastases, elderly patients, treatment safety, treatment efficacy
- MeSH terms
- Ipilimumab, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Age Factors, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Female, Graft Rejection, Head and Neck Neoplasms, Humans, Immunosuppressive Agents, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pregnancy, Pregnancy Complications, Neoplastic, HIV Infections, Immunocompromised Host, Hepatitis B, Chronic, Hepatitis C, Chronic, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
